Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of ascending oral doses of CHF 5074 administered once
per day for up to 12 weeks to patients with mild cognitive impairment.